Skip to main content

Table 2 Efficacy according to RECIST 1.0

From: Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

Efficacy in patients receiving treatment (n = 78)
  n %  
Response rate (evaluable n = 73)    (5 missing)
  Complete response 5 7  
  Partial response 23 31  
  Stable disease 31 43  
  Progressive disease or death 14 19  
   95% CI  
PFS rate at 9 months 0.35 0.24-0.46  
PFS 7.0 months 5.0-9.1  
OS 17.9 months 14.6-21.6  
  1. Abbreviations: n number, PFS Progression free survival, OS Overall survival, CI Confidence interval.